It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

 

 

Coding and billing

Verify payer-specific coding requirements. For reimbursement information, please contact Sandoz One Source.

HCPCS code Descriptor
C9058 Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo) 0.5 mg
Q5120* Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo) 0.5 mg
*effective as of July 1, 2020

 

Dosage form Package description 10-digit NDC1 11-digit NDC
Injection: clear, colorless to slightly yellowish solution supplied in a single-dose prefilled syringe for manual use containing 6 mg pegfilgrastim, supplied with a 27-gauge, 1/2-inch needle with an BD™ UltraSafe Passive® Needle Guard1 Pack of 1 sterile 6 mg/0.6 mL prefilled syringe 61314-866-01 61314-0866-01

 

Diagnosis code Descriptor
ICD-10-CM Allowable diagnosis codes vary by payer. Report the appropriate diagnosis code(s) to describe the patient's condition. Primary and secondary diagnosis codes may be required

CPT codes describe the therapeutic injection or infusion.

CPT code Descriptor
96372 Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular

 

SANDOZ one source contact information.

Contact Sandoz One Source

Call Sandoz One Source to enroll in support services
Fax Sandoz One Source to enroll in support services

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; NDC=National Drug Code.
BD is a trademark of Becton, Dickinson and Company. UltraSafe Passive is a registered trademark of Safety Syringes, Inc.

Reference: 1. ZIEXTENZO Prescribing Information. Sandoz Inc. September 2020.